New antibiotics in pulmonary and critical care medicine: Focus on advanced generation quinolones and cephalosporins

Seminars in Respiratory and Critical Care Medicine

Volumn 21, Issue 1, 2000, Pages 19-32

  Ambrose, Paul G ^c   Owens Jr , Robert C ^a,b  

^a MAINE MEDICAL CENTER   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c NONE   (United States)

Author keywords

Cephalosporins; Pharmacodynamics; Quinolones

Indexed keywords

CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN; CINOXACIN; CIPROFLOXACIN; CLINAFLOXACIN; DIGOXIN; ENOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MORPHINE SULFATE; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OXOLINIC ACID; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; SITAFLOXACIN; SPARFLOXACIN; STEROID 11BETA MONOOXYGENASE; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; INTENSIVE CARE; MINIMUM INHIBITORY CONCENTRATION; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 0034064469     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9927     Document Type: Review

References (85)

1. Eagle H, Fleischman R, Levy M. Continuous vs discontinuous therapy with penicillin. N Engl J Med 1953;238:481-488
2. Eagle H. Effect of schedule of administration on therapeutic efficacy of penicillin: Importance of aggregate time penicillin remains at effectively bactericidal levels. Am J Med 1950;9:280-299
3. Eagle H, Fleischman R, Musselman AD. Effective concentrations of penicillin in vitro and in vivo for streptococci and pneumococci, and Trepomena. J Bacteriol 1950;59:625-643
4. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96
5. Nishida M, Murakawa T, Kaminura T. Bactericidal activity of cephalosporins in an in-vitro model simulating serum levels. Antimicrob Agents Chemother 1978:14:6-12
6. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimum inhibitory concentration. J Infect Dis 1987;155:93-99
7. Prestom SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin. JAMA 1998;279:125-129
8. Fong IW, Cheng PC, Hinton NA. Fungicidal effect of amphotericin B in urine: In vitro study to assess feasibility of bladder washout for localization of site of candiduria. Antimicrob Agents Chemother 1991;35:1856-1859
9. Krieger JN, Dickins CS, Rein MF. Use of time-kill technique for susceptibility testing of Trichomonas vaginalis. Antimicrob Agents Chemother 1985;27:332-336
10. Lutsar I, Friedland IR, Wubbel L, et al. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneucoccal meningitis. Antimicrob Agents Chemother 1998;42:2650-2655
11. Forrest A, Nix DE, Ballow CH, Scgentag J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-1081
12. Lacy MK, Lu W, Xu X, Nicolau DP, Quintiliani R, Nightingale CH. Pharmacodynamic comparison of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother. 1999;43:672-677
13. Vesga O, Craig WA. Activity of levofloxacin against penicillin-resistant streptococcus pnemoniae in normal and neutropenic mice. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 15-18, 1996
14. Lee BL, Padula AM, Kimbrough RC. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991;325:520-521
15. Owens JC Jr, Ambrose PG, Quintiliani R. Antibiotic protein binding: Therapeutic implications. Antibiotics for Clinicians 1997;1:125-127
16. Craig WA, Shu B. Theory and practical impact of binding of antimicrobials to serum proteins and tissue. Scan J Infect Dis 1978;14(suppl):92-99
17. Shyu WC, Quintiliani R, Nightingale CH, Dudley MN. Effect of protein binding on drug penetration into blister fluid. Antimicrob Agents Chemother 1988;32:128-130
18. Rolinson GN. The significance of protein binding of antibiotics in bacterial chemotherapy. J Antimicrob Chemother 1980;6:311-317
19. Craig WA, Kunin CM. Significance of serum protein and tissue binding of antimicrobial agents. Annu Rev Med 1976;27:287-300
20. Grew RK, Moellering RC Jr. Effect of protein binding on activity of penicillins in combination with gentimicin against enterococci. Antimicrob Agents Chemother 1979;15:87-92
21. Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983;11:233-238
22. Moody JA, Peterson LR, Gerding DN. Cefoperazone treatment efficacy: Dependant on protein binding 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 17-20, 1985. Abstract 557
23. Andriole VT. The quinolones. In: Andriole VT, ed. The Quinolones, 2nd ed. San Diego, CA: Academic Press, 1998, 417-426
24. Stein GE. Pharmacokinetics and dynamics of newer quinolones. Clin Infect Dis 1996;23(suppl 1):s19-24
25. Raxar package insert, Glaxo Pharmaceutical, November 1997
26. Ambrose PG, Owens RC Jr, Quintiliani R, Nightingale CH. New generation quinolones. Conn Med 1997;61:269-272
27. Owens RC Jr, Ambrose PG, Quintiliani R, Nightingale CH. Classifying quinolone anti-infective agents by generation: A pharmacodynamic approach to rational drug selection. Antibiotics for Clinicians 1997;1:70-74
28. Owens RC Jr, Ambrose PG, Quintiliani R, Nightingale CH. Quinolones classified by generation: A pharmacodynamic analysis of respiratory tract and anaerobic pathogens. 32nd Annual ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 8, 1997
29. Domagala JM, Hanna LD, Heifetz CL, et al. New structure-activity relationships of the quinolone antibacterials useing the target enzyme: The development and application of a DNA gyrase assay. J Med Chem 1986;29:394-404
30. Domagala JM. Structure-activity and structure-side-effect relationshipsfor quinolone antibacterials. J Antimicrob Chemother 1994;33:685-706
31. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: Review of 95 cases. Clin Infect Dis 1994;18:946-950
32. Levoquin package insert. Ortho Pharmaceutical, December 1996
33. Lacreta F, Kollia G, Behr D, Stoltz R, Grasela D. Effect of a high-fat meal on the bioavailability of gatifloxacin in heathly volunteers. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998
34. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998
35. Asahina Y, Ishizaki T Suzue S. Recent advances in structure activity relationships in new quinolones. Prog Drug Res 1992;38:57-106
36. Hecht DW, Wexler HM. In vitro susceptability of anaerobes to quinolones in the United States. Clin Infect Dis 1996; 23(suppl 1):S2-S8
37. Peterson ML, Hovde LB, Wright DH, Hoang AD, Rotschafer JC. Trovafloxacin and levofloxacin resistance in Bacteroides fragilis. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998. Abstract E-32
38. Matsumoto M, Kojima K, Nagano H, Matsubara S, Yokata T. Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation. Antimicrob Agents Chemother 1992;36:1715-1719
39. Vohr HW, Wasinska G, Ahr HJ. Studies on the phatotoxic potential of BAY 12-8039. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996. Abstract F021
40. Kusajima H, Manita S, Yamamoto T, Hosaka M, Momo K. Phototoxicity and photochemical generation of reactive oxygen by new quinolones. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998. Abstract A-76
41. Ferguson J, Mcewen J, Goehler K, Mignot A. A double-blind, placebo- and positive-controlled, randomized study to investigate the phototoxic potential of gatifloxacin, a new fluoroquinolone antibiotic. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998. Abstract A-78
42. Hentge DJ, ed. Human Intestinal Microflora in Health and Disease. New York: Academic Press, 1993
43. Soleim HA, Scheline RR. Metabolism of xenobiotics by strains of intestinal bacteria. Acta Pharmacol Toxicol 1972; 31:471
44. Mathan VI, Wiederman J, Dobkin JF. Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora. Gut 1989;30:971-977
45. Lindenbaum J, Rund DG, Butler VP Jr. Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. N Engl J Med 1970;42:341-345
46. Kromer W. Endogenous and exogenous opioids in the control of gastroimtestinal motility and secretion. Pharmacol Rev 1988;40:121-162
47. Coupar IM. Opioid action on the intestine: the importance of the intestinal mucosa. Life Sci 1987;41:917-925
48. Trovan package insert. Pfizer Pharmaceuticals, January 1997
49. Morrow C, McArole C, Pettitt L, et al. Brief report: Pharmacokinetics of orally administered ciprofloxacin in abdominal surgery. Am J Med 1989;87(suppl 5A):86-88
50. Mizuki Y Fujiwari I, Yamaguchi T. Pharmcokinetic interations related to the chemical structures of fluoroquinolones. J Antimicrob Chemother 1996;37(suppl A):41-55
51. Sanders CC, Sanders WE Jr. Emergence of resistance to cefamandole: Possible role of cefoxitin-inducible β-lactamases. Antimicrob Agents Chemother 1979;15:792-797
52. Meideiros AA. Evolution and dessemination of beta-lactamases excellocted by generations of beta-lactam antibiotics. Clin Infec Dis 1997;24(Suppl 1):19-45
53. Knothe H, Shah P, Kremery V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11:315-317
54. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233-1237
55. Burke JP. Antibiotic resistance - Squeezing the balloon? JAMA 1998;280:1270-1271
56. Paterson DL, Ko W, Von Gottberg A, et al. In vitro susceptibility and clinical outcome of bacteremia due to extended-spectrum beta-lactamase (ESBL) producing Klebsiella pneumoniae. Clin Infect Dis 1998;27:956
57. Pfaller MA, Jones RN, Doern GV, et al. Bacterial pathogens from patients with bloodstream infections: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42:1762-1770
58. Jones RN, Pfaller MA, Doern GV, et al. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: A 1997 surveillance trial in 102 medical centers in the united states. Diagn Microbiol Infect Dis 1997;30:215-228
59. Jones RN, Marshall SA. Antimicrobial activity of cefepime tested against class C β-lactamase-producing strains resistant to ceftazidime: A multilaboratory national and international clinical isolate study. Diagn Microbiol Infect Dis 1994;19:33-38
60. Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis 1997;29:249-257
61. Sanders CC, Sanders WE Jr: Emergence of resistance during therapy with the newer β-lactam antibiotics: Role of inducible β-lactamases and implications for the future. Rev Infect Dis 1983;5:639-648
62. Sanders CC, Sanders WE Jr. β-lactam resistance in gram-negative bacteria: Global trends and clinical impact. Clin Infect Dis 1992;15:824-839
63. Johnson MP, Ramphal R. β-lactam resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990;162:981-983
64. Fussle R, Biscoping J, Behr R, et al. Development of resistance by Enterobacter cloacae during therapy of pulmonary infections in intensive care patients. Clin Invest 1994;72:1015-1019
65. Burwen DR, Banerjee SN, Gaynes RP, et al. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 1994;170:1622-1625
66. Quinn JP. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 1998;27(suppl 1): s117-s124
67. Ambrose PG, Richerson MA, Bui K, et al. Cost-effectiveness analysis of cefepime versus ceftazidime in ICU patients with hospital-acquired pneumonia. Clin Infect Dis 1998; 27:1046
68. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-590
69. Sanders WE Jr, Sanders CC. Enterobacter spp.: Pathogens poised to fluorish at the turn of the century. Clin Micro Rev 1997;10:220-241
70. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987;9:1065-1078
71. Aronoff SC, Shlaes DM. Factors that influence the evolution of β-lactam resistance in β-lactamase-inducible strains of Enterobacter cloacae and Pseudomonas aeruginosa. J Infect Dis 1987;155:936-941
72. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997;9(suppl 3):38-44
73. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-527
74. Sanders WE Jr, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant enterobacter species. Clin Infect Dis 1996;23:454-461
75. Chow AW, Wong J, Bartlett KH. Synergistic interactions of ciprofloxacin and extended-spectrum β-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia. Antimicrob Agents Chemother 1988;32:782-784
76. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994;38:1309-1313
77. Korvick JA, Bryan CS, Farber B, et al. Prospective observational study of klebsiella bacteremia in 230 patients: Outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992;36:2639-2644
78. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus β-lactam-aminoglycoside combination treatment for gramnegative bacteremia: A prospective, observational study. Antimicrob Agents Chemother 1997;41:1127-1133
79. Neu HC. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents. Drugs 1993;45(suppl 3):54-58
80. Stratton CW, Franke JJ, Weeks LS, et al. Comparison of the bactericidal activity of ciprofloxacin alone and in combination with selected antipseudomonal β-lactam agents against clinical isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 1989;11:41-52
81. Eliopoulos GM, Eliopoulos CT. Ciprofloxacin in combination with other antimicrobials. Am J Med 1989;87(suppl. 5A): 17s-22s
82. Tolzis P, Yamashita T, Vilt L. Antibiotic resistance does not alter endemic colonization with resistant gram-negative rods in a pediatric intensive care unit. Crit Care Med 1998; 26:1893-1896
83. Goldman M, Adelman MH, Thompson CE. Impact of conversion from ceftazidime to cefepime on ICU resistance patterns of Enterobacter cloacae. 8th International Congress of Infectious Diseases, Boston, Massachusetts, May 1998
84. Mebis J, Gossens H, Meeus I. Decreasing antibiotic resistance of inducible Enterobacteriaceae by introducing combination therapy. Blood 1996;88:505a
85. Owens RC, Jr, Owens CA, Holloway WJ. Comparative evaluation of a cefepime Q12-hour dosing schedule as empiric monotherapy infebril neutropenic patients. Pharmaco Ther 1999;19:496-497